HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Ro-23-9424

fused compound containing fleroxacin combined with desacetylcefotaxime; active against gram-positive bacteria

Also Known As:

Ro 23-9424

Networked: 5 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Infections 01/01/1990 - "In the control normal (immunocompetent) mouse infection, Ro 23-9424 was 3-fold more active than cefotaxime, but 10-fold less active than fleroxacin." 01/01/1990 - "Ro 23-9424 demonstrated significant activity against all strains tested in systemic infections, including those strains resistant in vivo to cefotaxime (Staphylococcus aureus 753, Serratia marcescens SM and Pseudomonas aeruginosa 8780) and fleroxacin (Streptococcus pneumoniae 6301 and Streptococcus pyogenes. " 04/01/1992 - "The MIC for 90% of isolates (MIC90) of Pseudomonas aeruginosa was 16.0 micrograms/ml. All group A and B streptococci were inhibited by less than or equal to 0.25 micrograms/ml, and 90% of group G streptococci and Streptococcus pneumoniae were inhibited by 1.0 micrograms/ml. All methicillin-susceptible strains of Staphylococcus aureus and 60% of methicillin-resistant strains were susceptible to 2.0 micrograms of Ro 23-9424 per ml, whereas the MIC90 for Staphylococcus epidermidis and Staphylococcus hominis isolates was 4.0 micrograms/ml. Staphylococcus haemolyticus and Enterococcus spp. were less susceptible; MIC90s for them were 16.0 and 32.0 micrograms/ml. Ro 23-9424 has a broad antibacterial spectrum and potential utility for therapy of infections in cancer patients." 03/01/1989 - "A novel fused co-drug of fleroxacin and desacetyl-cefotaxime, Ro 23-9424, was 100% effective against these Gram-positive pathogens at less than or equal to 8 micrograms/ml. Several of these compounds should receive consideration for clinical trials for empiric therapy among neutropenic patient infections where Gram-positive pathogens may be more prevalent."
2.	Pneumonia (Pneumonitis) 01/01/1990 - "In a murine pneumonia model, Ro 23-9424 was equivalent in activity to cefotaxime against S. "
3.	Neoplasms (Cancer) 04/01/1992 - "In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents." 04/01/1992 - "The MIC for 90% of isolates (MIC90) of Pseudomonas aeruginosa was 16.0 micrograms/ml. All group A and B streptococci were inhibited by less than or equal to 0.25 micrograms/ml, and 90% of group G streptococci and Streptococcus pneumoniae were inhibited by 1.0 micrograms/ml. All methicillin-susceptible strains of Staphylococcus aureus and 60% of methicillin-resistant strains were susceptible to 2.0 micrograms of Ro 23-9424 per ml, whereas the MIC90 for Staphylococcus epidermidis and Staphylococcus hominis isolates was 4.0 micrograms/ml. Staphylococcus haemolyticus and Enterococcus spp. were less susceptible; MIC90s for them were 16.0 and 32.0 micrograms/ml. Ro 23-9424 has a broad antibacterial spectrum and potential utility for therapy of infections in cancer patients." 04/01/1992 - "The in vitro activity of Ro 23-9424 against bacterial isolates from patients with cancer was compared with those of fleroxacin, ciprofloxacin, cefoperazone, and ceftazidime. "
4.	Necrosis 11/01/1996 - "In the LPS-treated cells, RO 23-9424 (100 mg/L) significantly (P < 0.05) enhanced the tumour necrosis factor-alpha (TNF-alpha) levels, compared with LPS controls after 4 h of incubation. "
5.	Body Weight (Weight, Body) 10/01/1990 - "To investigate these properties, Ro 23-9424 was administered as a single intravenous dose of 20 mg/kg of body weight to mice, rats, dogs, and baboons. "

Related Drugs and Biologics

1.	Fleroxacin
2.	Cefotaxime (Kendrick)
3.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
4.	Methicillin (Metin)
5.	Ciprofloxacin (Cipro)
6.	Ceftazidime (Fortum)
7.	Cefoperazone (Cefoperazone Sodium)
8.	Anti-Bacterial Agents (Antibiotics)

Related Therapies and Procedures

1.	Therapeutics